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Abstract
Background: We investigated whether the vitamin D3 receptor gene (VDR) polymorphism can modulate therapeutic response of functional 
hypothalamic amenorrhea (FHA) patients to the oestroprogestagen (EP) treatment.
Material and methods: The study included 84 FHA girls and 50 controls. FHA patients underwent a four-year sequential EP therapy 
with 17-b oestradiol (2 mg from the 2nd to 25th day of the menstrual cycle) and didrogesterone (10 mg from the 16th to the 25th day). Their 
hormonal parameters were monitored along with bone turnover marker levels and bone mineral density (BMD). Additionally, the VDR 
gene BsmI polymorphism was determined.
Results: Hormonal therapy was reflected by a substantial improvement of BMD. However, the values of BMD observed after four years of 
treatment in FHA patients were still significantly lower than baseline bone mineral density determined in the control group (1.007 ± 0.100 
vs. 1.141 ± 0.093 g/cm2, respectively; p < 0.001). No significant effects of the VDR genotype were observed on the dynamics of BMD dur-
ing consecutive years of hormonal treatment and mean bone mineral density determined after completing the therapy (1.006 ± 0.101 
vs. 1.013 ± 0.114 vs. 1.006 ± 0.094 g/cm2 for BB, bb and Bb genotypes, respectively; p = 0.973).
Conclusions: This study did not confirm that VDR polymorphism can modulate therapeutic outcome of FHA girls subjected to the hor-
monal treatment. Nonetheless, this study confirmed the effectiveness of EP therapy in the simultaneous treatment of menstrual disorders 
and the normalisation of bone mineral density in FHA patients. (Pol J Endocrinol 2011; 62 (6): 492–498)
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Streszczenie
Wstęp: Celem niniejszej pracy było sprawdzenie, czy polimorfizm genu receptora witaminy D3 (VDR) może warunkować odpowiedź na 
leczenie estroprogestagenami (EP) u pacjentek z brakiem miesiączki typu funkcjonalnego (FHA).
Materiał i metody: Badaniem objęto 84 pacjentek z FHA i 50 dziewcząt z grupy kontrolnej. U pacjentek z FHA zastosowano 4-letnią 
sekwencyjną terapię EP: 17-b estradiol (2 mg, 2.–25. dzień cyklu) i didrogesteron (10 mg, 16.–25. dzień cyklu). W trakcie leczenia kon-
trolowano parametry hormonalne, stężenia markerów obrotu kostnego oraz gęstość mineralną kości (BMD). Ponadto u każdej badanej 
określono polimorfizm BsmI genu VDR.
Wyniki: Leczenie hormonalne zaowocowało istotną poprawą BMD. Jednak wartości BMD stwierdzone po 4 latach terapii u pacjentek 
z FHA były wciąż znamiennie niższe niż w grupie kontrolnej (odpowiednio 1,007 ± 0,100 vs. 1,141 ± 0,093 g/cm2; p < 0,001). Nie wykazano 
znamiennego wpływu genotypu VDR na dynamikę zmian BMD w kolejnych latach terapii hormonalnej oraz średni poziom tego para-
metru po zakończeniu leczenia (odpowiednio 1,006 ± 0,101 vs. 1,013 ± 0,114 vs. 1,006 ± 0,094 g/cm2 dla genotypów BB, bb i Bb; p = 0,973).
Wnioski: Niniejsze badanie nie potwierdziło, by polimorfizm genu VDR wpływał na wyniki leczenia hormonalnego zastosowanego 
u pacjentek z FHA. Tym niemniej, niniejsze badanie wykazało przydatność terapii EP w jednoczesnym leczeniu zaburzeń miesiączkowania 
i normalizacji gęstości mineralnej kości u dziewcząt z brakiem miesiączki typu funkcjonalnego. (Endokrynol Pol 2011; 62 (6): 492–498)
Słowa kluczowe: gęstość mineralna kości, receptor witaminy D3, brak miesiączki typu funkcjonalnego, leczenie hormonalne, osteoporoza
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Introduction
Irregular menses are one of the possible consequences 
of an impairment of the somatosexual development in 
adolescent girls, which is described by psychologists as 
“juvenile crisis” [1]. Long-term exposure to stress can 
lead to functional hypothalamic amenorrhea (FHA), the 
prevalence of which is estimated at 2.6–8.5% [2], but 
this rises to 100% in cases of chronic exposure to stress, 
e.g. in females participating in certain sport disciplines 
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[3]. Stress is reflected by an enhanced release of the 
catecholamines norepinephrine and adrenaline, which 
via neuronal synapses stimulate a hypothalamic secre-
tion of corticotropin-releasing hormone (CRH). CRH 
inhibits the pulsatile release of gonadotropin-releasing 
hormone (GnRH) and activates pro-opiomelanocortin 
(POMC) and its derivatives, b-endorphin and adreno-
corticotropic hormone (ACTH). The activation of the 
hypothalamic-pituitary-adrenal axis (HPA) is reflected 
by an enhanced secretion of glucocorticoids, which in 
turn inhibits the release of GnRH, the pituitary gona-
dotropins FSH and LH, and oestradiol. High levels of 
b-endorphin, in turn, stimulate the secretion of prolac-
tin, which further inhibits the pulsatile release of GnRH 
and increases ACTH and glucocorticoid concentrations 
[4]. The activation of all the aforementioned mecha-
nisms leads to an impaired proliferation of the ovarian 
granulosa cells, a decreased synthesis of oestradiol, 
a disturbed maturation of the ovarian follicles, as well 
as disturbed ovulation cycles. These disruptions cause 
menstrual disorders, which are the principal manifesta-
tion of FHA [1, 5].
Apart from the direct impairment of sexual matu-
ration, FHA can also affect skeletal development in 
growing girls. Due to the antiresorptive and anabolic 
effects of oestrogens, a sufficient serum concentration 
of the latter is required for reaching peak bone mass 
[6, 7]. Therefore, menstruation disorders that are re-
lated to a decreased oestrogen concentration can be 
reflected by an inferior peak bone mass and a delayed 
growth, as well as an increased risk of postmenopausal 
osteoporosis [7].
Consequently, the implementation of an effec-
tive therapy of FHA-type menstrual disorders is of 
vital importance. Administration of oestrogens and 
progestagens in the form of oestroprogestagen (EP) 
therapy is the standard management in such cases. The 
principal objective of this treatment is to restore the 
proper concentrations of oestradiol and thus stimulate 
regular menses [8]. Our previous studies revealed 
that if implemented sufficiently early, EP therapy also 
results in the normalisation of bone mineral density. 
However, skeletal response to hormonal treatment was 
heterogeneous in patients who received EP [9–11]. The 
variability of the outcomes was partly explained by the 
polymorphisms of the oestrogen receptor gene [10, 11], 
but undoubtedly this factor is not the sole predictor of 
therapeutic response.
The vitamin D3 receptor (VDR) gene is another 
gene which could potentially be responsible for the 
degree of bone mineral density normalisation in re-
sponse to the hormonal treatment. Meta-analyses of 
the VDR gene polymorphism function suggested its 
possible associations with bone mineral density (BMD) 
and bone mineral content (BMC), as well as the risk of 
fractures in postmenopausal women [12, 13]. Vitamin 
D regulates the calcium and phosphorus metabolism, 
thus modulating BMD levels [14]. In turn, the VDR 
gene is responsible for proper interactions between 
the receptor and its ligand; furthermore, the VDR is 
the absolute determinant of the biological activity of 
1,25(OH)2D3 [15].
The results of previous studies suggest that the 
VDR gene polymorphism is associated with BMD, 
due to the fact that this receptor is a crucial mediator 
of the intestinal absorption of calcium, and thus of 
bone mineralisation in the lumbar spine in children, 
adolescent girls, and mature individuals of both 
genders, and also modulates the risk of fractures in 
elderly men and women [13, 16–19]. Additionally, 
some authors have claimed an interaction between 
oestrogen receptor-a and VDR genotypes with re-
spect to BMD [20].
In view of this evidence, we assumed that the VDR 
polymorphism can also modulate therapeutic response 
of FHA patients to the hormonal treatment imple-
mented to normalise menstrual disorders and prevent 
skeletal mass loss. The aim of this study was to verify this 
hypothesis on the basis of a four-year longitudinal study.
Material and methods
Participants
The study included 134 girls aged 16 and 17 years who 
were divided into two groups: 1) 84 patients with FHA, 
treated at the Department of Gynaecology, University 
of Medical Sciences in Poznan, Poland, between 2004 
and 2009 (Group A); and 2) 50 girls whose menstrual 
cycles were normal (controls, Group C).
All procedures were approved by the Local Ethics 
Committee of the University of Medical Sciences in 
Poznan. Both the subjects and their parents gave their 
informed consent before the start of any procedure.
Qualifying criteria for Group A included: 1) at least 
six months of amenorrhea preceded by at least three 
years of oligomenorrhea; 2) psychological problems 
(learning disability and/or family problems) confirmed 
by a clinical psychologist. Group A exclusion criteria, 
based on medical history and a standardised question-
naire survey [9], included the following: 1) polycystic 
ovary syndrome, congenital adrenal hyperplasia or pre-
mature ovarian failure; 2) low birth weight or preterm 
birth; 3) at least one confirmed episode of an eating 
disorder; 4) poor diet during childhood or puberty; 5) 
episodes of impaired growth and body mass gain; 6) 
extensive participation in sports that may have influ-
enced bone mineralisation; 7) metabolic disorders that 
may be associated with decreased bone mineralisation; 
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8) prolonged use of stimulants or drugs that may affect 
bone metabolism; 9) familial history of osteoporosis; and 
10) incomplete four-year follow-up (return of regular 
menstrual cycles, cessation of treatment due to medical 
indications or other reasons).
The control group comprised healthy, normally 
menstruating girls, who gave their consent to participate 
in this study due to prophylactic reasons.
Clinical and laboratory tests
Anthropometric measurements (height, body weight) 
were taken for all participants and their body mass index 
(BMI) was calculated. The development of secondary 
sexual characteristics was assessed using the Tanner 
scale [21]. Baseline values of hormonal parameters were 
determined for thyrotropin (TSH), follicle-stimulating 
hormone (FSH), luteinising hormone (LH), total serum 
testosterone (T), sex hormone binding globulin (SHBG), 
oestradiol (E2), and prolactin (PRL). The following bone 
turnover markers were also measured in both groups: 
serum concentration of the bone fraction of alkaline 
phosphatase (BALP) and the urine concentration of 
cross-linked n-telopeptide of type I collagen (Ntx). Bone 
mineral density (BMD) measurements were also per-
formed. Subjects in Group A were additionally tested 
for: blood morphology, erythrocyte sedimentation 
rate, and blood concentrations of calcium, phosphorus, 
creatinine, total protein, alkaline phosphatase, vitamin 
D3, and parathyroid hormone.
Oestradiol, TSH, FSH, and LH were measured in 
the serum using a solid-phase chemiluminescence 
immunoassay (Immulite; Diagnostic Products Co, Los 
Angeles, CA, USA). The assay sensitivity was 20 pg/ml 
for oestradiol, 0.01 mU/l for TSH, 0.1 mIU/ml for FSH, 
and 0.1 mIU/ml for LH. The intraassay and interassay 
coefficients of variation (CVs) for oestradiol were 9.3% 
and 10.5%, respectively, 1.9% and 5.0% for FSH, respec-
tively, and 3.6% and 5.0% for LH, respectively. Total 
serum testosterone was measured using an RIA (Orion 
Diagnostica, Espoo, Finland) with a 0.1 nmol/l limit of 
detection, and both intraassay and interassay CVs were 
of 6%. Sex hormone binding globulin (SHBG) was meas-
ured using a fully automated system (Immulite: DPC, 
Inc., Los Angeles, CA, USA), which uses a solid-phase 
two-site chemiluminescent enzyme immunometric as-
say, and has an interassay CV of less than 8%. Prolactin 
concentrations were determined by a microparticle 
enzyme immunoassay using the automated Abbott 
AxSYM system (Abbott Laboratories, Chicago, IL, USA). 
For prolactin, the within run CV was less than 3%, and 
the total CV was less than 6%.
Serum BALP was measured using a specific mono-
clonal antibody (Alkphase-B; Metra Biosystems, Moun-
tain View, CA, USA), with a 0.7 U/l sensitivity, and the 
intraassay and interassay CVs at 28 U/l amounted to 
3.3% and 7.9%, respectively. Ntx was measured in the 
morning sample of urine and was corrected for urinary 
creatinine. Measurements were carried out by means 
of an enzyme-linked immunoassay (VitrosTM NTX 
reagent pack; Ortho-Clinical Diagnostics, Amersham, 
UK), with a detection limit of 20 nmol bone collagen 
equivalent and an interassay CV of 4.1%.
BMD measurements were performed on the basis of 
the DXA method (GE Lunar Prodigy Advance, Madison, 
WI, USA; software enCORE version 8.8), using an au-
tomatic scan mode. Five measurements of the lumbar 
spine (L2-L4) BMD were carried out in the course of the 
treatment: 0 — as a baseline, and then after one, two, 
three and four years. Results were presented as absolute 
values (g/cm2) and relative changes (%).
Additionally, the VDR gene BsmI polymorphism 
was determined in subjects in Group A. In order to 
extract genomic DNA from peripheral blood mono-
nuclear cells using a non-enzymatic inorganic method 
[22], 10 ml of venous blood was collected and stored 
with an EDTA anticoagulant. BsmI polymorphism of 
the VDR gene was analysed according to Morrison 
[23]. DNA amplification was performed by means of 
the PCR method with pairs of the following primers 
flanking the polymorphic site: 5’-CAACCAAGAC-
TACAAGTACCGCGTCAGTGA-3’ as a sense VDR-se 
primer, and 5’-AACCAGCGGGAAGAGGTCAAGGG-3’ 
as an antisense VDR-as primer. An 800 bp-long product 
was obtained, and incubated at 37°C for three hours 
with a 2.5 U BsmI restriction enzyme (MBI Fermentas). 
This incubation resulted in three possible products: 1) 
bb genotype (confirmed presence of BsmI restriction 
site) — PCR product digested into 150 bp- and 650 
bp-long fragments of cDNA; 2) BB genotype (lack of 
BsmI restriction site) — undigested 800 bp-long PCR 
product; 3) heterozygous Bb genotype — combination 
of both aforementioned homozygous types (800 bp-, 
650 bp- and 150 bp-long products). DNA samples (40 
ng) were amplified in a 20 μl solution containing 4 
pM of either primer (VDR-se and -as), 2.0 mM of each 
deoxyribonucleotide triphosphate (dATP, dTTP, dCTP, 
dGTP; MBI Fermentas), PCR buffer (final concentration 
of magnesium: 1.5 mM MgCl2; MBI Fermentas) and 0.5 
units of Taq polymerase (MBI Fermentas). The amplifi-
cation was carried out under the following conditions: 
1) initial denaturation at 94°C for 5 min; 2) 35 cycles of 
denaturation at 94°C, 25 s each; 3) binding of primers, 
50 s at 60°C; and 4) elongation of the chain at 72°C for 
50 s. PCR was completed by a 10-minute elongation of 
the chain at 72°C. After digestion by the BsmI enzyme, 
PCR products were separated from the VDR primers 
by electrophoresis on a 3% ethidium bromide stained 
agarose gel.
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Intervention
Patients from Group A underwent a four-year sequential 
EP therapy with a preparation composed of the natural 
female sex hormone 17-b oestradiol (2 mg from the 2nd 
to 25th day of the menstrual cycle) and didrogesterone 
(10 mg from the 16th to the 25th day of the menstrual cycle). 
The goal of the treatment was for the patients to resume 
regular menstrual bleeding. Spontaneous menstruations 
did not resume in any of the participants and therefore 
the therapy was continued for four years. In addition to 
hormonal treatment, patients were encouraged to modify 
their lifestyles and dietary habits. They were prescribed 
calcium and vitamin D3 preparations at individual doses 
adjusted for their dietary content and for the season of 
the year. Moreover, regular physical activity (15 minutes 
of recreational gymnastics twice a day) was suggested.
Follow-up
Follow-up measurements of TSH, FSH, LH, T, SHBG, 
E2, and PRL, BALP and Ntx were performed after 
six months of EP treatment in patients belonging to 
Group A. Moreover, BMD measurements were carried 
out each year, starting 12 months after the initiation of 
EP therapy.
Statistical analysis
Continuous variables were presented as arithmetic 
means and their standard deviations (SD). Their 
normal distribution was tested using the Kol-
mogorov-Smirnov test. A logarithmic transformation 
was used for the Ntx variable. Arithmetic means be-
tween Groups A and C and among certain genotypes 
of the vitamin D3 receptor gene in Group A were 
compared with ANOVA and the Tukey post-hoc 
test. Mean values of parameters determined dur-
ing consecutive treatment phases in Group A were 
compared with Friedman ANOVA. Calculations were 
performed using Statistica 9.0PL (StatSoft® Inc. Tulsa, 
OK, USA) software, and statistical significance was 
defined as p ≤ 0.05.
Results
Prior to initiating the hormonal therapy, Group A pa-
tients differed significantly from the control group 
girls in terms of all analysed parameters other than 
BALP concentration (Table I). No significant effects 
of the VDR gene polymorphism were noted on an-
thropometric characteristics, hormonal profile, the 
levels of bone turnover markers, or BMD in Group A. 
In turn, the only significant association between VDR 
gene polymorphism and analysed parameters in the 
control group pertained to BMD, whose level was 
markedly higher in girls with BB genotype compared 
to other participants (1.246 ± 0.117 vs. 1.110 ± 0.081 
vs. 1.145 ± 0.084 g/cm2 for BB, bb and Bb genotypes, 
respectively; p = 0.010).
After six months of treatment, a significant im-
provement of all studied hormonal parameters was 
observed in Group A; however, these values were still 
significantly lower when compared to controls. Fur-
thermore, a significant decrease in Ntx along with 
Table I. Baseline characteristics of patients with functional hypothalamic amenorrhea (FHA) and the controls
Tabela I. Wyjściowe charakterystyki pacjentek z brakiem miesiączki typu funkcjonalnego (FHA)
Parameter Group A (n = 84) Group C (n = 50) p value
Mean SD Mean SD
Body height [cm] 162.27 6.63 166.82 6.04 < 0.001
Body weight [kg] 49.21 6.23 59.70 9.33 < 0.001
Menarcheal age [years] 14.05 1.12 12.46 0.71 < 0.001
Oestradiol [pg/ml] 22.75 8.41 60.06/133.86* 10.66/41.73* < 0.001/< 0.001*
Testosterone [ng/ml] 0.42 0.14 0.67 0.16 < 0.001
FSH [mIU/ml] 3.52 1.29 6.81 1.55 < 0.001
LH [mIU/ml] 1.63 1.18 9.49 2.09 < 0.001
PRL0 [ng/ml] 8.10 2.84 9.82 2.72 0.001
PRL60 [ng/ml] 144.30 49.59 81.99 19.69 < 0.001
BALP [U/ml] 39.44 13.81 40.27 13.51 0.736
Ntx [mEBCE/mg/ml CR] 407.59 230.89 49.39 21.65 < 0.001
BMD [g/cm2] 0.822 0.088 1.141 0.093 < 0.001
*depending on cycle phase
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a significant increase in BALP level were observed 
as a result of EP therapy; mean values of both bone 
turnover markers were significantly higher in Group 
A when compared to the control group (Table II). No 
significant effects of the VDR polymorphism were 
observed in Group A with regards to mean values of 
the parameters analysed after six months of therapy, 
nor their percentage change from respective baseline 
levels.
Hormonal therapy was reflected by a substantial 
improvement of BMD determined in consecutive 
years (Table III). However, the values of BMD observed 
after four years of treatment in Group A were still 
significantly lower than baseline bone mineral den-
sity determined in the control group (1.007 ± 0.100 
vs. 1.141 ± 0.093 g/cm2, respectively; p < 0.001). No 
significant effects of the VDR genotype were observed 
on the dynamics of BMD during consecutive years of 
hormonal treatment and mean bone mineral density 
determined after completing the therapy (1.006 ± 0.101 
vs. 1.013 ± 0.114 vs. 1.006 ± 0.094 g/cm2 for BB, bb and 
Bb genotypes, respectively; p = 0.973).
Discussion
This study confirmed our previous observations, 
which suggest that the administration of EP therapy 
can be reflected by improved bone mineral density 
in FHA girls [9, 11]. As early as six months into the 
treatment, significant improvement was observed 
in all hormonal parameters analysed in our group. 
Normalisation of the hormonal profile was accom-
panied by significant changes in the levels of bone 
turnover markers: decrease of Ntx and increase of 
BALP concentrations. These findings suggest an ini-
tiated process of normalisation of bone formation. 
Changes in the laboratory parameters were reflected 
by a significant increase of BMD, observed during 
consecutive years of the treatment. However, similar 
to our previous studies [9, 11], marked individual 
variability in the extent of treatment response was 
observed in our patients.
Many previous studies by other authors have docu-
mented an association between the polymorphism of 
the VDR gene and the level of BMD in adolescent 
Table II. Hormonal and bone turnover parameters after six months of EP therapy in Group A (n = 84) compared to baseline 
values in this group and baseline values of the controls (n = 50)
Tabela II. Parametry hormonalne i stężenie markerów obrotu kostnego po 6 miesiącach leczenia hormonalnego w grupie A 
(n = 84) w porównaniu z wartościami wyjściowymi w tej samej grupie i w grupie kontrolnej (n = 50)
Parameter Absolute value Relative change (%) p value 
(baseline)
p value 
(control group)Mean SD Mean SD
Oestradiol [pg/ml] 68.42 11.72 423.1 376.6 < 0.001 < 0.001/< 0.001*
FSH [mIU/ml] 5.35 1.27 70.4 80.5 < 0.001 < 0.001
LH [mIU/ml] 6.64 4.57 264.7 550.6 < 0.001 < 0.001
BALP [U/ml] 61.22 18.93 64.3 51.4 < 0.001 < 0.001
Ntx [mEBCE/mg/ml CR] 195.73 131.82 -51.4 18.6 < 0.001 < 0.001
*depending on cycle phase
Table III. Relative changes (%) in bone mineral density (BMD) during consecutive years of EP administered in Group A patients 
(n = 84)
Tabela III. Względne zmiany (%) gęstości mineralnej kości (BMD) w kolejnych latach leczenia hormonalnego pacjentek 
z grupy A (n = 84)
Year Overall (n = 84) BB genotype (n = 16) bb genotype (n = 30) Bb genotype (n = 38) p value
1 6.85 7.91 8.01 5.47 8.37 9.14 5.15 7.58 0.186
2 7.54 9.73 8.22 10.63 4.76 9.05 9.45 9.60 0.116
3 5.22 6.97 4.33 6.46 6.98 6.99 4.21* 7.07 0.440
4 2.39* 3.75 2.41 4.18 2.09* 3.14 2.62* 4.08 0.564
p value 0.009 0.193 0.045 0.046 –
Overall 23.38 13.79 24.78 15.07 23.47 12.81 22.72 14.31 0.621
*significantly different compared to previous years; SD — standard deviation
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girls [24–26]; therefore we assumed that the genotypic 
variability of this receptor can also modulate the level 
of therapeutic response in our group. However, this 
hypothesis was not confirmed by the results of our 
study: patients with various genotypes of VDR did not 
differ significantly in terms of baseline bone mineral 
density, or the dynamics of its changes in the course of 
hormonal treatment.
In our opinion, the nature of the underlying disease, 
along with the low representation of certain VDR geno-
types in our patients, constitute the principal reasons for 
the outcome of this study. FHA is a hormonal dysfunc-
tion, associated with a deficiency of oestrogens that are 
responsible for osteogenesis, among other functions [6, 
7]. Consequently, one can assume that the effectiveness 
of EP therapy is mostly determined by the ability to 
respond to hormonal substitution. This was confirmed 
both in our previous studies [9–11] and in experiments 
by other authors [27–29], all suggesting the involve-
ment of the oestrogen receptor-a gene polymorphisms 
in determining response to EP therapy. The principal 
function of VDR is to maintain normal levels of vita-
min D3 metabolism and compensate for its potential 
deficiencies [30]. In turn, all FHA patents participating 
in this study had normal serum levels of this vitamin, 
and received mineral and vitamin supplementation 
throughout the study period, fully covering recom-
mended requirements for vitamin D3 [31].
One should remember that none of the previous stu-
dies confirming the role of the VDR gene polymorphism 
in determining bone mineral density identified the exact 
mechanisms responsible for this phenomenon [15]. 
This mostly results from the complexity of the cascade 
responsible for the maintenance of the peak BMD. The 
process of bone mass normalisation is determined either 
by genetic factors or by environmental influences, and 
the mutual relationships between these two groups of 
factors [32, 33]. Apart from VDR, BMD is determined by 
other factors, such as the level of endogenous vitamin 
D (mostly dependent upon environmental influences), 
dietary supply and bioavailability of calcium, hormones 
involved in skeletal metabolism (parathyroid hormone, 
oestrogens and a variety of tissue hormones), as well as 
many others [34]. Also functional regulation of the vita-
min D3 receptor is a complex process — it is determined 
not only by the VDR genotype, but also by the type of 
skeletal tissue showing its expression [30].
Barring the complexity of biological processes in-
volved in BMD determination, methodological aspects 
can constitute another potential reason for discrepancies 
in the results of the previous research. The variability of 
the different sites at intron 8/exon 9 of the VDR gene, 
BsmI, ApaI and TaqI, and the FokI sites at exon 2.3, has 
been analysed during previous experiments, and diffe-
rent restriction enzymes were used. The most relevant 
data regarding the involvement of the VDR gene in the 
determination of bone mineral density pertains to the 
polymorphism of the FokI region. Several authors have 
observed that an FF genotype is associated with a better 
absorption of calcium, while an ff genotype frequently 
co-exists with bone mass deficiencies. However, the 
existing evidence regarding the role of BsmI polymor-
phism, analysed in our study, is conflicting. Some au-
thors have observed the highest BMD levels among car-
riers of homozygous genotypes of this polymorphism, 
BB or bb, while others have revealed Bb genotype as the 
predicator of high bone mineral density [24–26, 35–38]. 
Also our study did not elucidate the role of the BsmI 
polymorphism: we did not observe significant effects of 
this polymorphism on BMD in FHA patients; however, 
among patients from the control group, bone mineral 
density was significantly higher among carriers of BB 
genotype. While this latter finding is consonant with 
the observations of several authors [24], it nonetheless 
contrasts with the results obtained in a variety of other 
studies revealing this genotype to be predisposed to 
lower BMD [25, 26, 35–38].
Conclusions
Given the aforementioned facts, our current knowledge 
on the role of polymorphism of the VDR receptor gene 
in adolescent girls is still insufficient to be utilised in 
clinical practice. 
However, this does not diminish the principal out-
come of this study, which is to confirm the effectiveness 
of EP therapy in the simultaneous treatment of men-
strual disorders and the normalisation of bone mineral 
density in FHA girls. Nevertheless, further research 
is needed in order to find potential predictive factors 
that could be used for the identification of patients who 
could benefit most from the simultaneous supplementa-
tion of vitamin D and oestrogens.
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